In November 2019, an FDA panel of experts called the Endocrinologic and Metabolic Drugs Advisory Committee voted against the use of Jardiance to treat type 1 diabetes, given uncertainties about the risk of diabetic ketoacidosis and the lack of safety and efficacy data.